All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
Chimeric antigen T-cell (CAR-T) therapy has improved survival outcomes in patients but there is a gap in knowledge on why some patients do not improve after CAR T-cell therapy.1 Circulating tumor DNA (ctDNA) has become an emerging biomarker in many cancers used to predict CAR T-cell resistance and stratify the patients possible survival outcomes earlier.1
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition updates from three key trials assessing ctDNA as a tool to predict treatment response in patients with diffuse large B-cell lymphoma (DLBCL) were presented. Here, we summarize these updates; Foerster presented the association between ctDNA levels and CAR T-cell therapy,1 Jardin presented ctDNA analysis from the POLARIX trial (NCT03274492),2 and Alizadeh presented ctDNA analysis from the TRANSFORM trial (NCT03575351).3
Foerster presented a trial exploring the value of ctDNA in patients with R/R DLBCL treated with CAR T-cell therapy and the association between ctDNA and known clinical risk factors. In total 16 patients were included with 48 samples collected. ctDNA concentration was increased in patients with:
ctDNA concentration was decreased in patients with complete and partial metabolic response after bridging therapy but before CAR T-cell therapy. After treatment, patients with complete and partial metabolic responses showed a significant reduction in ctDNA levels, whereas those with stable or progressive disease had no significant ctDNA reduction.
Overall, pre-treatment ctDNA was associated with high-risk features and inferior progression-free survival (PFS) and overall survival in patients with DLBCL. ctDNA decreased one week after treatment in most cases and early ctDNA assessment after one week corresponds with early radiologic response after 4–6 weeks.
The Lymphoma Hub previously reported the primary results from the POLARIX trial. Jardin presented a substudy of the POLARIX trial assessing the mutational landscape and subtyping of DLBCL by plasma ctDNA (using AVENIO assay) vs tumor tissue (using whole genome sequencing assay). At baseline, 443 patients had tissue DNA and ctDNA data:
Table 1. 2-year PFS estimates of subtypes determined by tumor tissue vs ctDNA*
PFS in patients by subtype, %
Tumor tissue DNA
ctDNA, circulating tumor DNA, EZB, EZH2 mutations and BCL2 translocations; MCD, MYD88L265P and CD79B mutations; PFS, progression-free survival.
This data shows that the mutational landscape of tissue DNA determined by whole exome sequencing is captured when using ctDNA by AVENIO assay. Additionally, similar PFS outcomes were reported in patients with molecular subtypes defined by tissue or ctDNA; therefore, supporting the use of plasma ctDNA as an alternative to tumor tissue typing in patients with DLBCL. Consistency between tissue and ctDNA single nucleotide variants was 75% which demonstrated that further enhancement of ctDNA sequencing is required for future study.
Alizadeh presented data of a substudy from the TRANSFORM trial, previously summarized by the Lymphoma Hub. This trial met its primary endpoint with lisocabtagene maraleucel demonstrating higher event-free survival over the standard of care (52.6% vs 20.8%, respectively). Here, ctDNA-minimal residual disease levels were assessed in these patients to demonstrate surrogacy for disease burden and evaluate prognostic value (N = 184). Overall, prerandomization ctDNA levels correlated with:
Prerandomization ctDNA levels did not correlate with relapsed/refractory disease status or histology and cell or origin. After treatment:
Overall, this trial demonstrated the value of evaluating ctDNA levels in patients with non-Hodgkin lymphoma for disease surveillance as well as prediction of CR, durable clinical benefit, and risk of relapse.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from POLARIX trial
Here, we summarize an analysis investigating the safety and efficacy of polatuzumab vedotin in patients with previously untreated DLBCL in the Asia...
Lisocabtagene maraleucel as second-line therapy for adult patients with LBCL: Primary analysis of the phase III TRANSFORM trial
Primary analysis of the phase III TRANSFORM trial indicates that liso-cel has superior efficacy to standard of care for...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox